Patents Represented by Attorney Albert P. Pennie & Edmonds LLP Halluin
  • Patent number: 6025477
    Abstract: This invention provides purified antigens which are indicative of the presence of atherosclerotic plaque. Different concentrations of these antigens have been found to coincide with the progression of atherosclerosis. The subject invention also provides different hybridoma cell lines which produce monoclonal antibodies directed to antigens associated with atherosclerosis and a hybridoma cell line which produces monoclonal antibodies directed to antigen associated with normal artery and not with plaque. The atherosclerotic plaque antigen, and monoclonal antibodies made thereto, are used in various methods for detecting in a biological sample an antigen present in, and indicative of the presence of, atherosclerotic plaque. The monoclonal antibodies are also used in methods of imaging atherosclerotic plaque, and treating atherosclerosis. The methods of treating atherosclerosis include a method of digesting atherosclerotic plaque with enzymes, and a method of ablating atherosclerotic plaque using radiation.
    Type: Grant
    Filed: February 9, 1995
    Date of Patent: February 15, 2000
    Inventor: Emanuel Calenoff
  • Patent number: 5789166
    Abstract: The invention provides improved methods of introducing site-directed mutations into circular DNA molecules of interest by means of mutagenic primer pairs. The mutagenic primer pairs are also selected so as to be either completely complementary or partially complementary to each other, wherein the mutation site (or sites) is located within the region of complementarity. A mutagenic primer pair is annealed to opposite strands of a circular DNA molecule containing the DNA sequence to be mutagenized. After annealing, first and second mutagenized DNA strands, each incorporating a member of the mutagenic oligonucleotide primer pair is synthesized by a linear cyclic amplification reaction. After the linear cyclic amplification mediated synthesis step is completed, the reaction mixture is treated with a selection enzyme that digests the parental template strands. After the digesting step, a double-stranded circular DNA intermediate is formed.
    Type: Grant
    Filed: December 8, 1995
    Date of Patent: August 4, 1998
    Assignee: Stratagene
    Inventors: John C. Bauer, Dowain A. Wright, Jeffrey Carl Braman, Raif S. Geha
  • Patent number: 5773257
    Abstract: The present invention relates to an improved method for producing primed nucleic acid templates. Specifically, it relates to a method, compositions and kits therefor, of increasing the specificity of primer extension reactions by hybridizing primer to template in the presence of single-stranded nucleic acid binding protein.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 30, 1998
    Assignee: Stratagene
    Inventors: Kirk B. Nielson, Eric J. Mathur
  • Patent number: 5753674
    Abstract: The subject invention provides for novel compounds for inactivating viruses. These compounds include 6-nitroso-1,2-benzopyrone, 3-nitrosobenzamide, 5-nitroso-1 (2H)-isoquinolinone, 7-nitroso-1(2H)-isoquinolinone, 8-nitroso-1 (2H)-isoquinolinone. The invention also provides for compositions containing one or more of the compounds, and for methods of treating viral infections, cancer, infectious virus concentration with the subject compounds and compositions.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 19, 1998
    Assignee: Octamer, Inc.
    Inventors: Ernest Kun, Jerome Mendeleyev, William C. Rice
  • Patent number: 5698436
    Abstract: Epithelial cells expressing foreign genetic material are described. The foreign genetic material can be DNA or RNA which does not occur in epithelial cells; DNA or RNA which occurs in epithelial cells but is not expressed in them at levels which are biologically significant; DNA or RNA which occurs in epithelial and has been modified so that it is expressed in epithelial cells; and any DNA or RNA which can be modified to be expressed in epithelial cells, alone or in any combination thereof. In addition, epithelial cells of the present invention can express genetic material encoding a selectable marker by which cells expressing the foreign genetic material can be expressed.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 16, 1997
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Jeffrey R. Morgan, Richard C. Mulligan
  • Patent number: 5681726
    Abstract: The present invention provides an improved method for the synthesis of double stranded DNA, particularly complementary DNA for the construction of directional complementary DNA libraries. The method comprises synthesizing a first strand of DNA complementary to a selected RNA or DNA template by contacting with the template a linker/primer comprising a selected restriction site, a suitable RNA or DNA dependent DNA polymerase, and substrates comprising a deoxyribonucleotide triphosphate analog. The linker/primer and deoxyribonucleotide triphosphate analog are selected such that incorporation of the nucleotide analog in the first strand substantially protects the double stranded DNA from cleavage, under conditions sufficient to cleave or substantially cleave the linker/primer, at the selected restriction site.
    Type: Grant
    Filed: September 2, 1993
    Date of Patent: October 28, 1997
    Assignee: Stratagene
    Inventors: William David Huse, Connie Jo Hansen
  • Patent number: 5674722
    Abstract: Endothelial cells transduced with genetic material encoding a polypeptide or protein of interest and, optionally, a selectable marker, as well as methods for making and using the transduced endothelial cells are disclosed. Such endothelial cells are useful in improving the performance of vascular grafts and in delivering the encoded polypeptide or protein, such as an enzyme, a hormone, a receptor or a drug, to an individual.
    Type: Grant
    Filed: May 25, 1994
    Date of Patent: October 7, 1997
    Assignees: Somatix Therapy Corporation, Whitehead Institute For Biomedical Research, Brigham & Womens Hospital, Howard Hughes Medical Institute, New England Medical Center Hospitals
    Inventors: Richard C. Mulligan, Lawrence K. Cohen, Lori F. Rafield, Louis K. Birinyi, Allan D. Callow, James M. Wilson
  • Patent number: 5670518
    Abstract: Unsubstituted or substituted halo nitro and nitroso compounds and their metabolites are potent, selective and non-toxic inhibitors and supressants of cancer growth and viral infections in a mammalian host. The compounds are particularly useful for treatment and supression of tumors and viruses associated with breast cancer, AIDS, herpetic episodes and cytomegaloviral infections. The methods of treatment of tumorigenic and viral diseases by halo nitro and nitroso compounds and their metabolites are described.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 23, 1997
    Inventors: Ernest Kun, Jerome Mendeleyev, Eva Kirsten
  • Patent number: 5652260
    Abstract: The subject invention provides for novel compounds for inactivating viruses. These compounds include 6-nitroso-1,2-benzopyrone, 3-nitrosobenzamide, 5-nitroso-1(2H)-isoquinolinone, 7-nitroso-1(2H)-isoquinolinone, 8-nitroso-1(2H)-isoquinolinone. The invention also provides for compositions containing one or more of the compounds, and for methods of treating viral infections, cancer, infectious virus concentration with the subject compounds and compositions.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 29, 1997
    Assignee: Octamer, Inc.
    Inventors: Ernest Kun, Jerome Mendeleyev, William C. Rice
  • Patent number: 5637197
    Abstract: A suspension of bacterial cellulose having a reticulated structure has been conditioned to remain in suspension when the suspension is under shear so that it may be coated on a substrate. The suspension of bacterial cellulose is homogenized and thereafter filtered to provide a bacterial cellulose component having a size no greater than 125 microns. This allows a process for applying bacterial cellulose as a coating on a substrate on a substantially continuous basis, either by roll coating or spraying. It also provides a coated product in which the bacterial cellulose is substantially uniform, taking into account the normal discontinuities of roll coating and spray coating.
    Type: Grant
    Filed: December 17, 1993
    Date of Patent: June 10, 1997
    Assignee: Monsanto Company
    Inventors: Walter D. Watt, Terry N. Adams, Gary D. Peterson, R. Scott Stephens, James M. Askew